Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat for the Treatment of Anemia in Pediatric Participants With Chronic Kidney Disease
NCT05970172Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jan 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label, single-arm trial of roxadustat in anemia of chronic kidney disease, sponsored by Astellas Pharma. Primary endpoint: Change from baseline in Hemoglobin level. Started Jan 2024; status: active, not recruiting.
02
Drugs
roxadustat
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT05970172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970172.